EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Eirini Zacharopoulou, Eleni Orfanoudaki, Maria Tzouvala, George Tribonias, Georgios Kokkotis, Vassiliki Kitsou, Foteini Almpani, Aggeliki Christidou, Nikolaos Viazis, Gerassimos J Mantzaris iD, Maria Tsafaridou, Konstantinos Karmiris und 17 weitere

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac068 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Eirini Zacharopoulou und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, General Hospital of Nikaia Piraeus "Agios Panteleimon," General Hospital Dytikis Attikis "Agia Varvara," Athens, Gree…. Hauptthemen laut MEDLINE: COVID-19, Inflammatory Bowel Diseases, Viral Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Idiopathic Inflammatory Bowel Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Four EMA-approved vaccines against SARS-CoV-2 are currently available. Data regarding antibody responses to initial vaccination regimens in patients with inflammatory bowel diseases (IBD) are limited.

Methods

We conducted a prospective, controlled, multicenter study in tertiary Greek IBD centers. Participating patients had completed the initial vaccination regimens (1 or 2 doses, depending on the type of COVID-19 vaccine) at least 2 weeks before study enrolment. Anti-S1 IgG antibody levels were measured. Demographic and adverse events data were collected.

Results

We tested 403 patients (Crohn’s disease, 58.9%; male, 53.4%; median age, 45 years) and 124 healthy controls (HCs). Following full vaccination, 98% of patients seroconverted, with mRNA vaccines inducing higher seroconversion rates than viral vector vaccines (P = .021). In total, IBD patients had lower anti-S1 levels than HCs (P < .001). In the multivariate analysis, viral vector vaccines (P < .001), longer time to antibody testing (P < .001), anti-TNFα treatment (P = .013), and age (P = .016) were independently associated with lower anti-S1 titers. Vedolizumab monotherapy was associated with higher antibody levels than anti-TNFα or anti-interleukin-12/IL-23 monotherapy (P = .023 and P = .032). All anti- SARS-CoV-2 vaccines were safe.

Conclusions

Patients with IBD have impaired antibody responses to anti-SARS-CoV-2 vaccination, particularly those receiving viral vector vaccines and those on anti-TNFα treatment. Older age also hampers antibody production after vaccination. For those low-response groups, administration of accelerated or prioritized booster vaccination may be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Inflammatory Bowel DiseasesViral VaccinesHumansMaleMiddle AgedCOVID-19 VaccinesAntibody FormationProspective StudiesSARS-CoV-2VaccinationAntibodies, Viral

Stichwörter der Autor:innen

COVID-19 vaccinesCrohn’s diseaseIBDantibody responseulcerative colitis

Substanzen

COVID-19 VaccinesViral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Gastroenterology, General Hospital of Nikaia Piraeus "Agios Panteleimon," General Hospital Dytikis Attikis "Agia Varvara," Athens, Greece.
  • Department of Gastroenterology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion Crete, Greece.
  • GI Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian Univeristy of Athens- "Sotiria" General Hospital, Athens, Greece.
  • Department of Gastroenterology, General Hospital of Athens, Evaggelismos, Opthalmiatreion Athinon, Polykliniki, Athens, Greece.
  • Department of Gastroenterology, Venizelio General Hospital, Heraklion Crete, Greece.
  • Department of Gastroenterology, General Hospital of Athens "Alexandra," Athens, Greece.

ORCID-Profile: Gerassimos J Mantzaris, Giorgos Bamias

Förderung

  • Idiopathic Inflammatory Bowel Diseases

Zitieren

APA

Zacharopoulou, E., Orfanoudaki, E., Tzouvala, M., Tribonias, G., Kokkotis, G., Kitsou, V., Almpani, F., Christidou, A., Viazis, N., Mantzaris, G. J., Tsafaridou, M., Karmiris, K., Theodoropoulou, A., Papathanasiou, E., Zampeli, E., Michopoulos, S., Tigkas, S., Michalopoulos, G., Laoudi, E., …, & Bamias, G. (2023). Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac068

Vancouver

Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, et al. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac068

BibTeX
@article{Zacharopoulou2023,
  author = {Zacharopoulou, Eirini and Orfanoudaki, Eleni and Tzouvala, Maria and Tribonias, George and Kokkotis, Georgios and Kitsou, Vassiliki and Almpani, Foteini and Christidou, Aggeliki and Viazis, Nikolaos and Mantzaris, Gerassimos J and Tsafaridou, Maria and Karmiris, Konstantinos and Theodoropoulou, Angeliki and Papathanasiou, Evgenia and Zampeli, Evanthia and Michopoulos, Spyridon and Tigkas, Stefanos and Michalopoulos, Georgios and Laoudi, Efrossini and Karatzas, Pantelis and Mylonas, Iordanis and Kyriakos, Nikolaos and Liatsos, Christos and Kafetzi, Theodora and Theocharis, Georgios and Taka, Styliani and Panagiotopoulou, Konstantina and Koutroubakis, Ioannis E and Bamias, Giorgos},
  title = {Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac068}
}
Kostenlos starten →